PRECISEU Matchmaking Platform

20 Oct 2025 – 31 Jan 2026 | Barcelona, Spain

Register
Register
Register

Business OpportunityUpdated on 27 November 2025

PRISMA-AI-enabled Multimodal Decision-Support Integrating Clinical Notes and Biomarkers for Early Risk Stratification in Chronic Diseases

CEO at SYNOESIS THERAPEUTICS LTD

Heraklion, Greece

About

We have developed a TRL6 clinical-note NLP engine validated on large, real-world EHR datasets (ICU/ED; multilingual Greek/English), demonstrating consistent applicability across chronic-disease and multimorbidity contexts. Its prognostic risk outputs enable earlier and more effective management of chronic disease trajectories, with strong results in CKD and clear potential for neurological multimorbidity. Through PRECISEU, we aim to advance this NLP engine to TRL8 via deployment in multiple clinical regions and integration into routine workflows. Additionally, we have observed that adding biological biomarkers improves predictive performance. During the project, we will also integrate biomarker data from CKD and neurological patient cohorts to build a unified multimodal clinical decision-support companion. We seek hospitals with structured EHR notes (internal medicine, nephrology, neurology) and partners experienced in EHR integration to support deployment and validation of the platform in real clinical workflows.

Stage

  • TRL 6

Topic

  • Bioinformatics
  • Endocrine/nutritional/metabolic diseases
  • Mental and behavioural disorders / psychiatry /psychology
  • Diseases of the nervous system / neurology
  • Proteomics
  • Other

Sector

  • Health data
  • AI
  • Diagnostics

Type

  • Research collaboration
  • Co-development
  • Clinical validation
  • Consortium partners

Organisation

SYNOESIS THERAPEUTICS LTD

SME

Heraklion, Greece

Similar opportunities

  • Business Opportunity

    AI-powered Healthcare with therapeutic red blood cells

    • AI
    • TRL 6
    • ATMPs
    • Health data
    • Diagnostics
    • Rare diseases
    • Rare diseases
    • Co-development
    • Clinical validation
    • Regenerative medicine
    • Endocrine/nutritional/metabolic diseases
    • Diseases of the nervous system / neurology
    • Mental and behavioural disorders / psychiatry /psychology

    Denis Demarais

    Founder and CEO at Rius Medical

    Waldachtal, Germany

  • Business Opportunity

    NextPIDCAP: Implementing a standardized clinical decision support tool to enhance early identification of primary immunodeficiencies

    • TRL 6
    • TRL 7
    • TRL 8
    • Health data
    • Rare diseases
    • Research collaboration
    • Congenital or chromosomal abnormalities
    • Diseases of the blood and immune disorders

    Jacques Riviere

    Pediatric immunologist, researcher at Vall d'Hebron Research Institute (VHIR)

    Barcelona, Spain

  • Business Opportunity

    DIGITAL HEALTH CARE ASSISTANCE CHRONIC DISEASES

    • TRL 7
    • Respiratory
    • Health data
    • Rare diseases
    • Rare diseases
    • Co-development
    • Regulatory expert
    • Diseases of the ear
    • Consortium partners
    • External causes of morbidity, mortality
    • Endocrine/nutritional/metabolic diseases
    • Musculoskeletal system, connective tissue
    • Diseases of the nervous system / neurology
    • Mental and behavioural disorders / psychiatry /psychology

    Heike Heimann

    Company Management WIN5 at WIN5

    Stuttgart, Germany